Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, January 6 2025)

Image
By G.M.

 


    Antiviral Res

  1. GAO M, Zhang Z, Yao G, Zhang L, et al
    Design, synthesis, and biological evaluation of novel 2'-deoxy-2'-spirooxetane-7-deazapurine nucleoside analogs as anti-SARS-CoV-2 agents.
    Antiviral Res. 2024 Dec 30:106060. doi: 10.1016/j.antiviral.2024.106060.
    PubMed         Abstract available

  2. MERCURI FA, Anderson GP, Miller BE, Demaison C, et al
    Discovery and development of INNA-051, a TLR2/6 agonist for the prevention of complications resulting from viral respiratory infections.
    Antiviral Res. 2024 Dec 27:106063. doi: 10.1016/j.antiviral.2024.106063.
    PubMed         Abstract available


    BMJ

  3. DYER C
    Psychiatrist is struck off after claiming covid-19 vaccines lacked effectiveness and safety data.
    BMJ. 2024;387:q2888.
    PubMed        


    Clin Chem

  4. RAGLOW Z, Lauring AS
    Virus Evolution in Prolonged Infections of Immunocompromised Individuals.
    Clin Chem. 2025;71:109-118.
    PubMed         Abstract available

  5. CASTO AM, Paredes MI, Bennett JC, Luiten KG, et al
    SARS-CoV-2 Diversity and Transmission on a University Campus across Two Academic Years during the Pandemic.
    Clin Chem. 2025;71:192-202.
    PubMed         Abstract available


    Int J Infect Dis

  6. PETERSEN E, Hvid U, Tomori O, Pedersen AG, et al
    Possible scenarios for the spread of mpox outside the endemic focus in Africa.
    Int J Infect Dis. 2024 Dec 27:107373. doi: 10.1016/j.ijid.2024.107373.
    PubMed         Abstract available


    J Infect

  7. RUBIO R, Yavlinsky A, Zamudio ME, Molinos-Albert LM, et al
    Initial antigen encounter determines robust T-cell immunity against SARS-CoV-2 BA.2.86 variant three years later.
    J Infect. 2024 Dec 31:106402. doi: 10.1016/j.jinf.2024.106402.
    PubMed         Abstract available

  8. MENSAH AA, Stowe J, Brown K, LopezBernal J, et al
    COVID-19 reinfection in pregnancy: assessment of Severity and pregnancy outcomes in England.
    J Infect. 2024 Dec 27:106392. doi: 10.1016/j.jinf.2024.106392.
    PubMed         Abstract available

  9. MONK EJM, Foulkes S, Munro K, Atti A, et al
    Characterisation of the SARS-CoV-2 pandemic in healthcare workers within the United Kingdom: risk factors for infection during four successive waves.
    J Infect. 2024 Dec 27:106393. doi: 10.1016/j.jinf.2024.106393.
    PubMed         Abstract available


    J Med Virol

  10. LIU BM, Yao Q, Cruz-Cosme R, Yarbrough C, et al
    Genetic Conservation and Diversity of SARS-CoV-2 Envelope Gene Across Variants of Concern.
    J Med Virol. 2025;97:e70136.
    PubMed         Abstract available

  11. ZHAO X, Wei T, Hou Y, Wu Y, et al
    ATM/ATR-Mediated DNA Damage Response Facilitates SARS-CoV-2 Spike Protein-Induced Syncytium Formation.
    J Med Virol. 2025;97:e70137.
    PubMed         Abstract available

  12. CHEN J, Fan J, Malaviarachchi PA, Post SR, et al
    Alterations in Cellular Gene Expression Due to Co-Infection With Kaposi's Sarcoma-Associated Herpesvirus and SARS-CoV-2: Implications for Disease Severity.
    J Med Virol. 2025;97:e70149.
    PubMed         Abstract available


    J Virol

  13. ZHU J, Lai Y, Cheng M, Dash RC, et al
    Discovery of small molecules against porcine reproductive and respiratory syndrome virus replication by targeting NendoU activity.
    J Virol. 2024 Dec 31:e0203424. doi: 10.1128/jvi.02034.
    PubMed         Abstract available


    Life Sci

  14. SHAFQAT A, Li M, Zakirullah, Liu F, et al
    A comprehensive review of research advances in the study of lactoferrin to treat viral infections.
    Life Sci. 2025;361:123340.
    PubMed         Abstract available


    Nature

  15. LEFRANCQ N, Duret L, Bouchez V, Brisse S, et al
    Learning the fitness dynamics of pathogens from phylogenies.
    Nature. 2025 Jan 1. doi: 10.1038/s41586-024-08309.
    PubMed         Abstract available


    Science

  16. COHEN J
    Learning from a pandemic many are forgetting.
    Science. 2025;387:10-11.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »